ClinicalTrials.gov
ClinicalTrials.gov Menu

Early Glargine (Lantus) in DKA Management in Children With Type 1 Diabetes

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03107208
Recruitment Status : Recruiting
First Posted : April 11, 2017
Last Update Posted : June 12, 2018
Sponsor:
Information provided by (Responsible Party):
University of Colorado, Denver

Brief Summary:
A frequent complication in the management of diabetic ketoacidosis (DKA) in children with type 1 diabetes is rebound hyperglycemia (blood glucose over 180 mg/dL) which increases the risk of re-developing DKA and can lengthen the hospital stay. The investigators want to study whether giving the long-acting insulin glargine (Lantus®) early in DKA management (versus after complete resolution of the DKA) helps prevent rebound hyperglycemia and makes the transition to insulin injections easier. Participants will also have the option to wear a continuous glucose monitor (CGM) during the study to help us understand blood glucose control during and after DKA.

Condition or disease Intervention/treatment Phase
Diabetic Ketoacidosis Type 1 Diabetes Mellitus Drug: Glargine Device: Continuous Glucose Monitor (Abbott FreeStyle Libre Pro) Phase 4

Detailed Description:
Diabetic ketoacidosis (DKA) remains the leading cause of morbidity and mortality in children with type 1 diabetes (T1D) and the incidence of T1D is increasing. A frequent complication in DKA management that is associated with in-hospital mortality and longer hospital stay is hyperglycemia; specifically rebound hyperglycemia (defined as a serum glucose greater than 180 mg/dL) within 12-24 hours after correction of the DKA. Rebound hyperglycemia increases the patient's risk of re-developing DKA. Few adult studies suggest that giving the long-acting insulin analog (glargine or Lantus®) early in the management of DKA (i.e. while still receiving intravenous insulin) can reduce rebound hyperglycemia without an increased risk of hypoglycemia and result in a smoother transition from intravenous insulin to subcutaneous insulin. This has not been well-studied in children to date. In this study the investigators want to determine whether giving glargine early in DKA management in children results in reduced rebound hyperglycemia without an increased risk in hypoglycemia. The investigators will do this by randomizing participants in DKA to either receive glargine early in the management of DKA (study group) or after resolution of DKA (control group); the latter is currently standard-of-care. Additionally, continuous glucose monitoring (CGM) systems have not been studied in a pediatric population with DKA. These devices measure blood sugar levels every 5 minutes and provide a great deal of information about blood sugar control patterns over many days. Not only will the use of CGM in this study provide meaningful information regarding blood sugar patterns during DKA treatment, it will also broaden the investigators knowledge of whether CGM is a feasible and accurate tool to use in this setting.

Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 100 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Management of Diabetic Ketoacidosis in Children: Does Early Glargine Prevent Rebound Hyperglycemia?
Actual Study Start Date : July 21, 2017
Estimated Primary Completion Date : June 2018
Estimated Study Completion Date : July 2018

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: Early glargine (Lantus)
A dose of glargine (Lantus®) is given subcutaneously early in the management of DKA (i.e. while the participant is still receiving intravenous insulin). Participants will also be asked to wear a continuous glucose monitor (CGM) during the DKA and for a week following the DKA.
Drug: Glargine
A dose of glargine (Lantus) will be given subcutaneously either early in the management of DKA (study group) or upon resolution of DKA (control group).
Other Name: Lantus

Device: Continuous Glucose Monitor (Abbott FreeStyle Libre Pro)
All participants will be asked to wear a continuous glucose monitor (CGM) during the DKA and for a week following the DKA in order to better understand blood glucose control during DKA. This is an optional part of the study.
Other Name: CGM

Control group
A dose of glargine (Lantus®) is given subcutaneously after resolution of the DKA (i.e. when the intravenous insulin is stopped). This is currently the standard-of-care practice for children in DKA. Participants will also be asked to wear a continuous glucose monitor (CGM) during the DKA and for a week following the DKA.
Drug: Glargine
A dose of glargine (Lantus) will be given subcutaneously either early in the management of DKA (study group) or upon resolution of DKA (control group).
Other Name: Lantus

Device: Continuous Glucose Monitor (Abbott FreeStyle Libre Pro)
All participants will be asked to wear a continuous glucose monitor (CGM) during the DKA and for a week following the DKA in order to better understand blood glucose control during DKA. This is an optional part of the study.
Other Name: CGM




Primary Outcome Measures :
  1. Rate of Rebound Hyperglycemia [ Time Frame: Within 12 hours after resolution of diabetic ketoacidosis ]
    Evaluate the rate of rebound hyperglycemia with a glucometer, defined as a serum glucose level of greater than 180 mg/dL (>10 mmol/L) within 12 hours after discontinuation of IV insulin, in children treated for diabetic ketoacidosis (DKA) with early glargine versus standard-of-care management.


Secondary Outcome Measures :
  1. Rate of Recurrent Ketogenesis [ Time Frame: Within 12 hours after discontinuation of IV insulin ]
    Evaluate the rate of recurrent ketogenesis (beta-hydroxybutyrate ≥ 1.5 mmol/L within 12 hours after discontinuation of IV insulin) in children treated for diabetic ketoacidosis (DKA) with early glargine versus standard-of-care management.

  2. Risk of Hypoglycemia between those given early administration of glargine versus those given standard-of-care management. [ Time Frame: During treatment and within 12 hours after d/c IV insulin; while receiving IV insulin in children with DKA given early glargine versus standard-of-care management. ]
    Assessment of the frequency of hypoglycemic events during treatment of DKA, and within 12 hours after discontinuation of IV insulin, in children given early glargine versus standard-of-care management vs. the rate of blood glucose decrease while receiving IV insulin in children with DKA given early glargine versus standard-of-care management.

  3. Evaluation of CGM and POC glucose monitoring during DKA treatment in children. [ Time Frame: During treatment of DKA and within 12 hours after discontinuation of IV insulin. ]
    Evaluation of the feasibility and utility of CGM as a tool to monitor blood glucose levels during DKA treatment in children.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   6 Years to 18 Years   (Child, Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  1. Age 6-17.9 years at time of enrollment.
  2. Known history of type 1 diabetes or presumed new-onset type 1 diabetes.
  3. Diagnosis of DKA (serum glucose or fingerstick glucose concentration ≥ 200 mg/dL.
  4. Venous pH ≤7.3 and/or serum bicarbonate concentration ≤15 mmol/L.
  5. Evidence of ketonemia or ketonuria).

Exclusion Criteria:

  1. Participants who present in DKA with conditions that affect neurological function such as:

    1. suspected alcohol or drug use,
    2. severe head trauma,
    3. meningitis, etc., who would not be able to consent/assent for the study.
  2. Participants who present in DKA who are showing signs of altered mental status at time of enrollment.
  3. Other known complicating illness or poorly-controlled chronic illness that is known to affect blood glucose levels and/or electrolyte balance such as:

    1. chronic renal disease (requiring hemodialysis),
    2. chronic liver disease (with evidence of current hepatic dysfunction,
    3. coagulopathy, and/or chronic hepatitis), or
    4. severe chronic lung disease (requiring the use of oral steroids).
  4. Use of medications that are known to affect blood glucose levels such as:

    1. oral glucocorticoids,
    2. Metformin,
    3. SGLT2 inhibitors,
    4. GLP-1 receptor agonists,
    5. DPP-4 inhibitors,
    6. thiazolidinediones
    7. sulfonylureas, and
    8. vasopressors, etc.
  5. Participants who have begun DKA treatment prior to being approached for enrollment and have received more than 6 hours of IV insulin therapy.
  6. Participants who are known to be pregnant.
  7. Participants who have a known diagnosis of type 2 diabetes.
  8. Participants for whom the treating physicians feel a specific insulin regimen is necessary such that patient safety or well-being could be compromised by enrollment into the study.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03107208


Contacts
Contact: Rebecca A Ohman-Hanson, MD 720-777-2560 rebecca.ohman@childrenscolorado.org
Contact: Guy T Alonso, MD 303-724-2323 guy.alonso@ucdenver.edu

Locations
United States, Colorado
Children's Hospital Colorado Recruiting
Aurora, Colorado, United States, 80045
Contact: Kathleen Grice    303-724-3285      
Contact: Regan Miller    303-724-2592      
Principal Investigator: Rebecca A Ohman-Hanson, MD         
Sponsors and Collaborators
University of Colorado, Denver
Investigators
Principal Investigator: Rebecca Ohman-Hanson University of Colorado, Denver

Responsible Party: University of Colorado, Denver
ClinicalTrials.gov Identifier: NCT03107208     History of Changes
Other Study ID Numbers: 16-1965
First Posted: April 11, 2017    Key Record Dates
Last Update Posted: June 12, 2018
Last Verified: June 2018
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Product Manufactured in and Exported from the U.S.: No

Keywords provided by University of Colorado, Denver:
DKA
type 1 diabetes
children
continuous glucose monitoring

Additional relevant MeSH terms:
Diabetic Ketoacidosis
Diabetes Mellitus
Diabetes Mellitus, Type 1
Ketosis
Glucose Metabolism Disorders
Metabolic Diseases
Endocrine System Diseases
Autoimmune Diseases
Immune System Diseases
Acidosis
Acid-Base Imbalance
Diabetes Complications
Insulin Glargine
Hypoglycemic Agents
Physiological Effects of Drugs